Clinical trial design in the age of molecular profiling

Methods in Molecular Biology

Volumn 823, Issue , 2012, Pages 19-34

  Spira, Alexander ^a   Edmiston, Kirsten H ^b  

^a Virginia Cancer Specialists   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Biomarkers; Clinical trial; Design; End points; Imaging; Pharmacodynamics; Tumor

Indexed keywords

ANIMAL; ARTICLE; CLINICAL TRIAL (TOPIC); GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; SIGNAL TRANSDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RESEARCH DESIGN; SIGNAL TRANSDUCTION;

EID: 82355181790     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60327-216-2_2     Document Type: Article

References (47)

1. Pazdur, R. (2008) Endpoints for assessing drug activity in clinical trials. Oncologist 13 Suppl 2, 19-21.
2. Glynne-Jones, R., Mawdsley, S., Pearce, T., Buyse, M. (2006) Alternative clinical end points in rectal cancer-are we getting closer? Ann Oncol 17, 1239-48. (Pubitemid 44288215)
3. Schuetze, S. M., Baker, L. H., Benjamin, R. S., Canetta, R. (2008) Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 13 Suppl 2, 32-40.
4. Scott, J., McGettigan, G. (2005) Regulatory approvals for oncology products based on accelerated clinical development and limited data packages-2. Regulatory Rapporteur 2, 6-15.
5. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L. et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92, 205-16.
6. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F. et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-90.
7. Alves, R. C., Alves, D., Guz, B., Matos, C., Viana, M., Harriz, M. et al. (2011) Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 10, 21-7.
8. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M. et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356, 125-34. (Pubitemid 46089673)
9. Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45, 228-47.
10. Hillner, B. E., Siegel, B. A., Liu, D., Shields, A. F., Gareen, I. F., Hanna, L. et al. (2008) Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 26, 2155-61.
11. Evelhoch, J., Garwood, M., Vigneron, D., Knopp, M., Sullivan, D., Menkens, A. et al. (2005) Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res 65, 7041-4. (Pubitemid 41161229)
12. van Rijswijk, C. S., Geirnaerdt, M. J., Hogendoorn, P. C., Peterse, J. L., van Coevorden, F., Taminiau, A. H. et al. (2003) Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results. Eur Radiol 13, 1849-58. (Pubitemid 36949711)
13. Reid, A. H., Baird, R., Workman, P. (2008) Emerging molecular therapies: Drugs interfering with signal transduction pathways, in Principles of Molecular Oncology (Bronchud, M. H., Foote, M., Giaccone, G., Olopade, O., and Workman, P., ed.), Humana Press, Totowa, NJ, pp. 325-329.
14. Weissman, C. H., Reynolds, C. H., Neubauer, M. A., Pritchard, S., Kobina, S., Asmar, L. (2011) A phase III randomized trial of gemcitabineoxaliplatin versus carboplatin-paclitaxel as fi rstline therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 6, 358-64.
15. Therasse, P., Carbonnelle, S., Bogaerts, J. (2006) Clinical trials design and treatment tailoring: general principles applied to breast cancer research. Crit Rev Oncol Hematol 59, 98-105. (Pubitemid 44094104)
16. Mandrekar, S. J., Sargent, D. J. (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 27, 4027-34.
17. Mandrekar, S. J., Sargent, D. J. (2010) Predictive biomarker validation in practice: lessons from real trials. Clin Trials 7, 567-73.
18. Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C. et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26, 3543-51.
19. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M. et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 351, 2817-26. (Pubitemid 40051905)
20. Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W. et al. (2006) Gene expression and benefi t of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24, 3726-34. (Pubitemid 46622311)
21. van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W. et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347, 1999-2009. (Pubitemid 35461656)
22. van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M. et al. (2002) Gene expression profi ling predicts clinical outcome of breast cancer. Nature 415, 530-6. (Pubitemid 34130608)
23. Sparano, J. A. (2006) TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7, 347-50. (Pubitemid 44717771)
24. Sparano, J. A., Paik, S. (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26, 721-8. (Pubitemid 351264384)
25. Oakman, C., Santarpia, L., Di Leo, A. (2010) Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 7, 725-32.
26. Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L., Hortobagyi, G. N. (2008) Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13, 477-93. (Pubitemid 351872866)
27. Bogaerts, J., Cardoso, F., Buyse, M., Braga, S., Loi, S., Harrison, J. A. et al. (2006) Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 3, 540-51. (Pubitemid 44781724)
28. Cardoso, F., Van't Veer, L., Rutgers, E., Loi, S., Mook, S., Piccart-Gebhart, M. J. (2008) Clinical application of the 70-gene profi le: the MINDACT trial. J Clin Oncol 26, 729-35. (Pubitemid 351264385)
29. Schaeybroeck, S. V., Allen, W. L., Turkington, R. C., Johnston, P. G. (2011) Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2011.15
30. Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., Schnitt, S. J. (1999) Specifi city of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17, 1983-7. (Pubitemid 29318825)
31. Elkin, E. B., Weinstein, M. C., Winer, E. P., Kuntz, K. M., Schnitt, S. J., Weeks, J. C. (2004) HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22, 854-63. (Pubitemid 41103597)
32. Bartlett, J. M., Going, J. J., Mallon, E. A., Watters, A. D., Reeves, J. R., Stanton, P. et al. (2001) Evaluating HER2 amplifi cation and overexpression in breast cancer. J Pathol 195, 422-8. (Pubitemid 33069666)
33. Goldenberg, M. M. (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21, 309-18. (Pubitemid 29157789)
34. Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J. et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131, 18-43. (Pubitemid 46174133)
35. Roche, P. C., Suman, V. J., Jenkins, R. B., Davidson, N. E., Martino, S., Kaufman, P. A. et al. (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94, 855-7. (Pubitemid 34705058)
36. McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., Clark, G. M. (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93, 387-91. (Pubitemid 43080010)
37. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L. et al. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14, 737-44.
38. Arteaga, C. L., Baselga, J. (2003) Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin Cancer Res 9, 1579-89. (Pubitemid 36554579)
39. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A. et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783-92. (Pubitemid 32222155)
40. Ciardiello, F., Tortora, G. (2008) EGFR antagonists in cancer treatment. N Engl J Med 358, 1160-74.
41. Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H. J. et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357, 2040-8. (Pubitemid 350106711)
42. Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C. et al. (2008) K-ras mutations and benefi t from cetuximab in advanced colorectal cancer. N Engl J Med 359, 1757-65.
43. Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J. et al. (2008) Wild-type KRAS is required for panitumumab effi cacy in patients with metastatic colorectal cancer. J Clin Oncol 26, 1626-34.
44. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefi tinib. N Engl J Med 350, 2129-39. (Pubitemid 38637993)
45. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S. et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefi tinib therapy. Science 304, 1497-500. (Pubitemid 38720929)
46. Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Janne, P. A. et al. (2008) First-line gefi tinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26, 2442-9.
47. Sheehan, K. M., Calvert, V. S., Kay, E. W., Lu, Y., Fishman, D., Espina, V. et al. (2005) Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4, 346-55. (Pubitemid 40590555)